The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
Open accessAbstract
Treatment-emergent suicidal ideation and behavior are ongoing concerns with antidepressants. Vilazodone, currently approved for the treatment of major depressive disorder (MDD) in adults, has also been evaluated in generalized anxiety disorder (GAD). Post-hoc analyses of vilazodone trials were carried out to examine its effects on suicidal ideation and behavior in adults with MDD or GAD. Data were pooled from vilazodone trials in MDD (four studies) and GAD (three studies). The incidence of suicide-related events was analyzed on the basis of treatment-emergent adverse event reporting and Columbia-Suicide Severity Rating Scale (C-SSRS) monitoring. Treatment-emergent suicidal ideation was analyzed on the basis of a C-SSRS category shift from no suicidal ideation/behavior (C-SSRS=0) at baseline to suicide ideation (C-SSRS=1-5) during treatment. In pooled safety populations (MDD, n=2233; GAD, n=1475), suicide-related treatment-emergent adverse events occurred in less than 1% of vilazodone-treated and placebo-treated patients. Incidences of C-SSRS suicidal ideation were as follows: MDD (vilazodone=19.9%, placebo=24.7%); GAD (vilazodone=7.7%, placebo=9.4%). Shifts from no suicidal ideation/behavior at baseline to suicidal ideation during treatment were as follows: MDD (vilazodone=9.4%, placebo=10.3%); GAD (vilazodone=4.4%, placebo=6.1%). Data from placebo-controlled studies indicate little or no risk of treatment-emergent suicidal ideation or behavior with vilazodone in adults with MDD or GAD. Nevertheless, all patients should be monitored for suicidal thoughts and behaviors during antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Contrary to earlier FDA findings, SSRIs may work without increasing risk of treatment-emergent suicidal ideation or behavior, even in youth.(67–69)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although there is little evidence of sexual dysfunction (Shi, Wang, Xu, & Lu, 2016) and of treatment-emergent suicidal ideation (Thase et al., 2017)”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Thase et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“The FDA also requires clinical trials of new psychotropic drugs to include a prospective assessment of suicidal ideation and behavior using instruments such as the Columbia-Suicide Severity Rating Scale (C-SSRS) (Posner et al., 2011).”
MethodKessler, R. C. (2005) · JAMA · doi:10.1001/jama.293.20.2487 · Cited by 1,073
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609 · cited 3×
“First, several metaanalyses of clinical trial data have found no overall association between FDA-approved antidepressants and the emergence of suicidal ideation or behavior in adults, although some increase in risk has been observed in younger adults (≤ 24 years) (Khan et al., 2003; Stone et al., 2009; Gibbons et al.,…”
BackgroundMethodSuicide Risk During Antidepressant Treatment
Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.41 · Cited by 424 · cited 1×
“In addition, an analysis of healthcare claims data found no significant increase in suicides or suicide attempts after initiation of antidepressant treatment; rather, the highest risk of suicide attempt occurred in the month before treatment initiation (Simon et al., 2006).”
BackgroundKhan, A., Khan, S., Kolts, R., & Brown, W. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.790 · Cited by 394
Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2048 · Cited by 291
The Relationship Between Antidepressant Prescription Rates and Rate of Early Adolescent Suicide
Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1898 · Cited by 289
Barbui, C., Esposito, E., & Cipriani, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081514 · Cited by 275
Persisting Decline in Depression Treatment After FDA Warnings
Libby, A. M., Orton, H. D., & Valuck, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.46 · Cited by 169
Cited by
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060864 · Cited by 655
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Zhang, Y., Zheng, G., Fu, T., Hong, J., Li, F., Yao, X., Xue, W., & Zhu, F. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp05764a · Cited by 48
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021004 · Cited by 38
Wang, L., Zhang, Y., Du, X., Ding, T., Gong, W., & Liu, F. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109408 · Cited by 35
Metadata
- Authors
- Thase, M. E., Edwards, J., Durgam, S., Chen, C., Chang, C.-T., Mathews, M., & Gommoll, C. P.
- Affiliations
- Allergan (United States) (US)
- Corresponding author
- Thase, Michael E.
- Venue
- International Clinical Psychopharmacology
- Published
- 2017-09
- Volume
- 32
- Issue
- 5
- Pages
- 281-288
- ISSN
- 0268-1315 (ISSN-L)
- PMC
- PMC5540350
- OpenAlex
- W2616544698
- Cited by
- 11
- References
- 24
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- International Clinical Psychopharmacology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Forest Research Institute
- Allergan
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- vilazodone, suicidal ideation, suicidal behavior, major depressive disorder, generalized anxiety disorder, antidepressant safety, treatment-emergent adverse events, Columbia Suicide Severity Rating Scale, serotonin reuptake inhibitors
- MeSH terms
- Vilazodone Hydrochloride, Adult, Anxiety Disorders, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Suicide, Attempted, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials. https://app.cochat.ai/papers/10.1097/yic.0000000000000180
- The paper
- Thase, M. E., Edwards, J., Durgam, S., Chen, C., Chang, C.-T., Mathews, M., & Gommoll, C. P. (2017). Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.